Download Dana-Farber Cancer Institute, Inc.

Dana-Farber Cancer Institute, Inc.
General Information
450 Brookline Avenue
Boston, MA 02115
(617) 632-3000
Website
www.dana-farber.org
Organization Contact
Caitlin Fink [email protected]
Year of Incorporation
1947
1
Statements & Search Criteria
Mission Statement
Founded in 1947, Dana-Farber Cancer Institute’s mission is to provide expert, compassionate care
to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure
and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a
Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also
provides training for new generations of physicians and scientists, designs programs that promote
public health particularly among high-risk and underserved populations and disseminates innovative
patient therapies and scientific discoveries in Boston, across the United States and throughout the
world.
Background Statement
In 1947, Sidney Farber, MD, founded the Children's Cancer Research Foundation, dedicated to
providing compassionate, state-of-the-art treatment to children with cancer while developing cancer
preventatives, treatments and cures of the future. The foundation officially expanded its programs to
include patients of all ages in 1969, and in 1974 became known as the Sidney Farber Cancer
Center. The long-term support of the Charles A. Dana Foundation was acknowledged by
incorporating the Institute under its present name in 1983.
Today, Dana-Farber employs over 4,000 people supporting more than 350,000 patient visits a year
and participates in nearly 700 clinical trials. Its international reputation for blending research and
clinical excellence uniquely positions the Institute to develop and test the next generation of cancer
therapies in both the laboratory and the clinic.
Dana-Farber is a principal teaching affiliate of Harvard Medical School, a federally designated
Center for AIDS Research and the founding member of the Dana-Farber/Harvard Cancer Center, a
federally designated comprehensive cancer center comprised of seven Harvard-affiliated hospitals
and more than 900 investigators who have made astounding discoveries and continue to work
tirelessly to translate those discoveries into better approaches for diagnosis and treatment.
Providing advanced training in cancer treatment and research for an international faculty, the
Institute conducts community-based programs in cancer prevention, detection, and control
throughout New England, and maintains joint programs with other Boston institutions affiliated with
Harvard Medical School and the Partners Health Care System, including Brigham and Women's
Hospital, Boston Children's Hospital and Massachusetts General Hospital.
Dana-Farber is supported by the National Cancer Institute, the National Institute of Allergy and
Infectious Diseases, and the generous support of numerous foundations and individuals who
contribute to the Institute's research and clinical programs or to The Jimmy Fund, the principal
charity of the Institute, named for one of its child patients.
2
Impact Statement
th
Ranked New England’s best and the country’s 5 best cancer hospital by U.S. News & World
Report, Dana-Farber’s equal commitment to research & patient care is unique among cancer
institutions. This 50-50 balance results in extraordinary partnerships between laboratory scientists
and clinicians to ensure that each patient’s medical, psychological, family and spiritual needs are
addressed throughout their entire cancer journey. Regardless of age, teams of multi-disciplinary
experts focusing on the same type of cancer collaborate to offer novel therapies to patients and
access to innovative clinical trials. Our network of support services is comprehensive and
specialized to address unique patient needs at every stage of treatment and life. Last year, the
Institute treated more than 47,000 adult patients through 350,000 visits in 13 specialized centers;
and the Jimmy Fund Clinic treated more than 2,400 patients through nearly 15,000 visits.
Dana-Farber’s history of groundbreaking discoveries traces back to its founder, Dr. Sidney Farber,
the “father of chemotherapy”, and first physician to attain remissions of acute lymphoblastic
leukemia, the most common childhood cancer. In the 1970s, our scientists pioneered combination
chemotherapy, using multiple drugs to treat cancer more effectively. In the 1980s, the Institute was
the first to implement autologous bone marrow transplantation, a life-saving procedure that reduces
the risk of transplant rejection due to imperfect matches. Also in the 1980s, Dana-Farber scientists
identified the human T-cell receptor, a key mechanism that led to vastly increased understanding of
HIV/AIDS. In 2011, we launched Profile, one of the most extensive genotyping projects in cancer
research nationally, allowing the Dana-Farber/Brigham and Women’s Cancer Center to test all
consenting patients’ tumor tissue for nearly 500 cancer-causing mutations in 41 cancer genes and
generate data to better understand the causes, treatments and prevention of cancer.
Needs Statement
Dana-Farber is proud to be at the forefront of dramatic advances in cancer research and treatment
and remains committed to conquering all forms of cancer. Our successes to date would not have
been possible without the partnership of generous donors. While we have made great strides, there
is still much work to be done to develop better treatments to improve outcomes for all who suffer
from this insidious disease. Unrestricted funds are enormously important because they can be
directed where and when they are needed most, helping to ensure that we have the necessary
flexibility to sustain novel research and seize every opportunity in patient care, without financial
restraints imposed by economic downturns and a challenging federal funding climate. Such
fundsallowus to be nimble in our tireless pursuit to better understand,treat and ultimately eradicate
cancer. Among many other priorities, your support will bolster the Institute’s ability to address
patients’ and families’ medical and psychosocial needs; provide seed funds for the most innovative
early stage investigations not yet eligible for federal funding; educate the wider community about the
importance of cancer prevention and screening; and support training programs for the next
generation of scientists in the fight against cancer.
Service Categories
Hospitals
Hospitals
Fund Raising & Fund Distribution
Geographic Areas Served
Dana-Farber Cancer Institute has partnerships with the following adult outpatient centers and
considers these satellite locations:
• Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) at Faulkner Hospital in Jamaica
3
Plain, Massachusetts
• DF/BWCC at Milford Regional Medical Center in Milford, Massachusetts
• Dana-Farber/New Hampshire Oncology-Hematology in Londonderry, New Hampshire
• DF/BWCC in clinical affiliation with South Shore Hospital in Weymouth, Massachusetts
Please review online profile for full list of selected areas served.
4
Programs
A. Patient Care
Description
Dana-Farber provides outpatient careto adult patients in 13
specialized centers and partners with Brigham and Women’s
Hospital to provide inpatient care. Pediatric patients receive
outpatient care at our Jimmy Fund Clinic and inpatient care is
provided by Children's Hospital Boston.
Budget
$.00
Category
Health Care, General/Other Patient Care/Health Care Delivery
Population Served
Adults, ,
Program Short Term Success
The Yawkey Center for Cancer Care, which opened in February
2011, adds 275,000 square feet of clinical and support space and
is designed to accommodate more than 100 exam rooms, more
than 150 infusion spaces, and 20 consultation rooms. This clinical
care facilitywas designed with advice from patients, families, and
staff to advance clinical care, optimize patient safety, enhance the
patient experience, and provide an environment that fosters
healing. Programs and resources such as our pioneering use of
ERSA-C (Electronic Self-Report Assessment-Cancer), a first-ofits-kind computer program that helps patients track their
symptoms and allow doctors to monitor them between visits, and
our pilot of a real-time locating system to identify the locations of
patients and staff and reduce wait times ensure that all of our
patients’ physical, emotional, and spiritual needs are met during
and ease the burden of cancer treatment.
Program Long term Success
U.S. News & World Report’s Best Hospitalsguide ranked DanaFarber/Brigham and Women's Cancer Center the top cancer
th
center in New England, for the 12 year in a row, and fifth overall
in the country. Dana-Farber and Children's Hospital Boston was
ranked as the #2 pediatric cancer hospital in the United States in
its 2011-12 Best Children's Hospitals guide. This combined
ranking reflects the clinical and scientific strength and depth of
the Dana-Farber/Children's Hospital Cancer Center, a partnership
of more than 60 years that provides comprehensive care to
children with cancer and survivors of pediatric cancers.
5
Program Success Monitored By
We set standards for our own practices and measure ourselves
against other comprehensive cancer centers nationwide. We
measure five different aspects of patient care: effectiveness,
patient and family satisfaction, safety, equitable access, and
timeliness. In addition, U.S. News & World Reportpublishes its
Best Hospitals guide each year as a reference for patients who
are reviewing their medical care options. The overall score is
based on professional reputation, mortality rates, patient safety,
and a grouping of care-related factors such as nursing and patient
services.
Examples of Program Success
At Griffin’s 8-week checkup, his pediatrician found that his belly
was abnormally large and sent him to Children’s Hospital. After
the test results came in, pediatric oncologist Dr. Lindsay Frazier
met with the family to explain Griffin's cancer. This was a hard
conversation for Griffin's parents, but Dana-Farber/Children's
Hospital Cancer Center (DF/CHCC) "had a psychologist available
to speak with us, which helped emotionally," says Griffin’s mother,
Melissa. "And Dr. Frazier even called us at home the following
Saturday to ask how we were managing."
Griffin's cancer was called neuroblastoma and his care was
transferred to two specialists at DF/CHCC. By the time he was 10
months old, Griffin had beaten cancer.
Looking back, Melissa feels lucky to live so close to Dana-Farber.
"I know it sounds odd, but I looked forward to going to the Jimmy
Fund Clinic because we genuinely felt that everyone there cared
about us. It was a good place for us during that period of our
lives."
6
B. Research
Description
Research, both basic and clinical, remains at the core of our
mission. Our researchers are currently trailblazing the concept of
personalized medicine, tailoring therapies to each patient, to
develop less invasive and toxic treatments.
Budget
$.00
Category
Medical Research, General/Other Cancer Research
Population Served
Adults, Children and Youth (0 - 19 years),
Program Short Term Success
In 2011, the Dana-Farber/Brigham and Women’s Cancer Center
boldly and successfully launched Profile, one of the most
comprehensive cancer research studies to help accelerate the
development of personalized treatments for every person with
cancer to be undertaken nationally. This major research study
tests all consenting adult patients’ tumor tissue for nearly 500
genetic cancer-causing mutations in 41 cancer genes,
using OncoMaptechnology, a novel screening approach
discovered at Dana-Farber. The study will provide researchers
with one of the world’s largest databases of cancer genetic
abnormalities. Over time, this growing body of information will help
scientists discover more about the genetic causes of cancers and
increase the development of new, targeted therapies to treat
them.
Program Long term Success
Dana-Farber is committed to translating basic research findings
into clinical applications to ultimately improve treatments and
outcomes for patients with all types of cancer. We seek to better
understand drug resistance and disease relapse and overcome
them through the continued development of targeted and effective
“smart” drugs, which attack cancer cells but not normal ones. For
example, in 2008, Dana-Farber scientists achieved a medical first
by using a targeted drug to drive a patient's metastatic melanoma
into remission. When lab tests showed the patient's tumor cells
harbored a certain mutated gene, doctors treated her with a drug
that blocks the gene's action, resulting in a dramatic reduction in
tumor size and activity. In 2011, we received FDA approval for the
first drug approved for advanced melanoma in more than 10
years. Over the next decade, the continued translation of our
basic discoveries into informed drug development for more
effective therapies is a top priority.
7
Program Success Monitored By
The Office of Research Support Services provides financial and
administrative oversight for research at Dana-Farber. The Clinical
Trials Office (CTO) develops policies, procedures, and best
practices related to clinical trials; coordinates submission and
compliance of protocols; assists in the pre-review of protocols
before submission for approval; provides guidance related to the
operational conduct of a trial, regulatory matters, and multi-center
site issues; and facilitates clinical research center (CRC)
recruitment, on-boarding and training and oversight and
management of CRC teams. The goal of the CTO is to help
assure that a clinical trial protocol is well written, able to be
conducted at Dana-Farber and will meet the requirements for
scientific review and Institutional Review Board.
Examples of Program Success
Dana-Farber's George Demetri, MD, designed and led
an international Phase 3 clinical trial of regorafenib, a new
targeted drug that can significantly control life-threatening
metastatic disease in patients with gastrointestinal stromal tumors
(GIST) that have developed resistance to Gleevec and Sutent, the
only two FDA-approved drugs available for this disease. The trial
determined that treatment with regorafenib reduces the risk of
disease progression or death by more than 70 percent in these
patients. In another trial, the novel compound selumetinib has
become the first targeted therapy to benefit patients with the most
common genetic subtype of lung cancer, non-small cell lung
cancer. This study confirmed that chemotherapy and selumetinib
might be an effective treatment for KRAS-mutant lung cancer and
have implications for the treatment of all cancers that harbor
KRAS mutations, including pancreatic and colorectal cancer.
8
C. Training
Description
A teachingaffiliate of Harvard Medical School, DFCI supports
participation by its professional staff in medical education, clinical
training, and pre-doctoral and post-doctoral research training.
Budget
$.00
Category
Medical Research, General/Other Cancer Research
Population Served
Adults, Children and Youth (0 - 19 years),
Program Short Term Success
Dana-Farber is keenly aware that future advances in cancer
medicine lie in the imaginations of the talented physicians and
scientists poised to be the leaders of tomorrow. The Postdoctoral
and Graduate Student Affairs Office supports trainees’
professional development through programs on manuscript
writing, grant writing, and laboratory management. Dana-Farber
attracts the finest researchers and clinicians in the world, and its
junior faculty members benefit from extensive professional
development opportunities. All members of the Institute's
professional staff hold faculty appointments at Harvard University,
and many participate as mentors for institutional graduate and
postdoctoral training programs. It is a source of great pride that so
many of Dana-Farber’s former trainees are now principal
investigators and institutional leaders here and at cancer centers
around the world.
Program Long term Success
Dana-Farber faculty are consistently recognized for their
excellence in medical education, research and clinical training.
The Institute offers formal opportunities for career development
and implements diversity initiatives to increase the quality and
balance of the professional lives of our young faculty. Examples of
these innovative programs include the Office for Faculty
Development, the Office of Diversity and Talent Management,
both of which offer unique teaching and mentoring programs, and
access to multiple multi-institutional programs such as those
offered through Harvard Catalyst and Dana-Farber/Harvard
Cancer Center. Contributing to our efforts to increase the pipeline
of future cancer researchers, the Institute also supports
instructional programs with high schools, colleges, and community
groups that enable underserved students to work in Dana-Farber
laboratories and begin their careers in science.
9
Program Success Monitored By
Biannually, Dana-Farber’s faculty and staff complete an opinion
survey as part of efforts to create an ideal work environment. The
survey consists of nearly 50 questions (some open-ended) on
core values, work environment, organizational performance,
diversity and inclusion, pay and benefits and supervisor/staff
relationships. The purpose of the survey is to define levels of staff
satisfaction/engagement, determine strengths and areas of
opportunity, promote honest feedback, gauge if past
actions/improvements have been successful and use the results
to plan for future improvements. Results from the 2011 survey
revealed that Dana-Farber scored 4.23 out of 5 for workplace
satisfaction/commitment, outperforming national academic health
care average and ranking in the 87th percentile of large academic
medical health care organizations. High marks were received in
quality care/service to patients, connection to the mission and
values, and sense of pride in working for Dana-Farber.
Examples of Program Success
The Pediatric Hematology/Oncology Fellowship Program at DanaFarber/Children's Hospital Cancer Center (DF/CHCC) is one of
the most recognized in the nation and has trained more leaders in
the hematology and oncology field than any other. The program
admits six new fellows per year who spend one year in full-time
clinical work and two or more years in research training,
depending on previous training and interests. The program is
geared to broadly train MD or MD/PhD fellows in areas of clinical
research, including outcomes, ethics, epidemiology, therapeutic
trials and translational research, or in one of the major basic
science disciplines: protein chemistry, structural biology,
molecular biology, stem cell and developmental biology, genetics,
genomics, immunology, systems biology, neuroscience or cell
biology.
10
D. Community Based Programs
Description
Dana-Farber promotes health in the Greater
Boston community through its Community Benefits Program,
which brings cancer education & resources to at-risk populations,
and through its Center for Community-Based Research,
which conducts research to reduce disparities in cancer care.
Budget
$.00
Category
Health Care, General/Other Public Health
Population Served
At-Risk Populations, Adults, Children and Youth (0 - 19 years)
Program Short Term Success
Dana-Farber’s Community Benefits Program aims to make DanaFarber's care and research findings more accessible to everyone,
including our neighbors in local communities. The Institute is
committed to bringing cancer prevention and education initiatives
to an increasing number of members of the Greater Boston
community. Dana-Farber physicians are also committed to
educating the public about cancer risk reduction, screening and
early detection, and treatment options and survivorship. They
reach out to Greater Boston communities to heighten awareness
and answer questions through: ongoing presentations at
partnering high schools; educational sessions to physicians and
patients at community health centers; working with faith-based
organizations and in collaboration with the Boston Ministerial
Alliance; and speaking engagements to the elderly at low-income
housing sites.
Program Long term Success
The Institute’s community benefits mission is threefold: to
establish quantifiable and sustainable cancer prevention programs
focusing on at-risk and underserved populations; provide
expertise in cancer care to city and state health departments,
community-based agencies and health care providers; and
increase accrual of minorities into clinical trials. In addition to
bringing cancer prevention, education and resources directly to
diverse, at-risk, underserved populations, the Institute also
conducts a broad scope of research to identify new interventions
that reduce health disparities and improve access to care.
11
Program Success Monitored By
To ensure that Dana-Farber’s community outreach activities and
programs are meeting the health needs in the community, DanaFarber’s Community Benefits Office partnered with Health
Resources in Action (HRiA), a non-profit public health consultancy
organization in Boston, to undertake a comprehensive community
health assessment. In Phase I, social, economic, and
epidemiological data at the community level were reviewed and
analyzed to provide a health portrait of Dana-Farber’s priority
communities (Roxbury, Mission Hill, Dorchester, Mattapan, and
Jamaica Plain). Phase II involved a comprehensive qualitative
study, where Dana-Farber staff, community leaders, and residents
provided feedback in focus groups and interviews to identify
community needs and assets as well as areas for further
community engagement and program expansion. The needs
assessment final report was completed in early 2012.
Examples of Program Success
Dana-Farber's Mammography Van is the only mobile
mammography program in the Commonwealth of Massachusetts.
It provides screening mammograms and breast health education
to women age 40 and older.In partnership with community-based
organizations and neighborhood health centers, the Van serves all
Boston neighborhoods and some surrounding towns. Skilled,
board-certified mammography technologists from Dana-Farber
perform the exams and films are interpreted by board-certified
radiologists. By bringing Dana-Farber's high-quality services
directly to the neighborhoods in which women live and work, the
Van breaks down cultural, linguistic, financial, and logistical
barriers to care and makes mammograms more accessible to
women who might otherwise not have access to screening.
Likewise, the Patient Navigator Program helps to remove barriers
to cancer care for diverse women with low socio-economic status,
limited English proficiency, disabilities, or lack of insurance.
12
Management
CEO/Executive Director
Executive Director
Dr. Edward J. Benz, Jr.
Term Start
Jan 2000
Email
[email protected]
Experience
Edward J. Benz, Jr., MD, became the president and chief executive officer of Dana-Farber in 2000
and also serves as chief executive officer of Dana-Farber/Partners Cancer Care, director of DanaFarber/Harvard Cancer Center, and as a trustee of Dana-Farber/Children's Hospital Cancer Care.
Dr. Benz is presently the Richard and Susan Smith Professor of Medicine, professor of Pediatrics,
professor of Pathology, and faculty dean for Oncology at Harvard Medical School. He received a
bachelor's degree, cum laude, from Princeton University; a medical degree, magna cum laude, from
Harvard Medical School; and a master's degree (privatum) from Yale University. Immediately prior
to assuming the presidency of the Institute, Dr. Benz was chairman of the Department of Medicine
at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine.
Author of more than 200 articles, books, chapters, reviews, and abstracts, he is a past president of
both the American Society of Hematology and the American Society of Clinical Investigation, and is
currently an associate editor of the New England Journal of Medicine.
Senior Staff
Dorothy E. Puhy
Title
Executive Vice President and Chief Operating Officer
Experience/Biography
Dorothy E. Puhy became the Institute's chief operating officer in
2012. She previously served as chief financial officer and director
for Fiscal Services since 1994, and executive vice president since
2004. Ms. Puhy is chief administrative officer of DanaFarber/Partners CancerCare and treasurer of HealthCare
Dimensions, Inc.
Prior to joining Dana-Farber, she was chief financial officer at
New England Medical Center in Boston and a senior manager at
Ernst and Whinney. Ms. Puhy received her bachelor's degree
from the University of Pennsylvania and her business degree
from its Wharton School.
Karen Bird
Title
Chief Financial Officer and Assistant Treasurer
Experience/Biography
Karen Bird joined Dana-Farber in 1999 and became chief financial
officer and assistant treasurer in 2012. She had previously served
as senior vice president for Finance since 2007. Prior to coming to
Dana-Farber, Ms. Bird held positions at Faulkner Hospital, where
she served as vice president for Network Development, and at
New England Medical Center, where she was vice president of
Finance. She received a bachelor's degree from Trinity College
and a graduate degree from the Harvard School of Public Health.
13
Susan D. Block MD
Title
Chair, Department of Psychosocial Oncology and Palliative Care
Experience/Biography
Susan D. Block, MD is the Chair of the Department of
Psychosocial Oncology and Palliative Care at Dana-Farber and
Brigham and Women's Hospital and Co-Director of the Harvard
Medical School Center for Palliative Care, a national center of
excellence in palliative care education. Dr. Block received her AB
from Stanford University, her MD from Case Western Reserve
University School of Medicine, and completed residencies in both
internal medicine and psychiatry at Beth Israel Hospital in Boston.
She is board-certified in both fields and in palliative medicine.
Richard S. Boskey
Title
Senior Vice President and General Counsel
Experience/Biography
Richard S. Boskey joined the Institute in 1999. He serves as
assistant secretary of Dana-Farber Cancer Institute and DanaFarber/Partners CancerCare, and secretary of the Dana-Farber
Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care.
Previously, he served in various positions at Partners HealthCare
and Massachusetts General Hospital, including deputy general
counsel, and was an associate at the law firm Hill & Barlow. Mr.
Boskey received his bachelor's degree from Brown University and
his master's and law degrees from the University of Virginia.
Beverly R. Ginsburg Cooper MBA
Title
Senior Vice President for Research
Experience/Biography
Beverly R. Ginsburg Cooper came to Dana-Farber in November
2006 from the University of Pennsylvania, where she served for
16 years as executive director of the Abramson Cancer Center.
Prior to that, Ms. Ginsburg Cooper was president of Medical
Partnerships, Inc., vice president of Pennsylvania Hospital, and
chief operating officer of a community hospital.
Ms. Ginsburg Cooper received her bachelor's degree in
education from Adelphi University and her MBA from the Wharton
School of the University of Pennsylvania. Currently, she is
president of the Cancer Center Administrators Forum and a
member of the external advisory boards of several
comprehensive cancer centers.
14
James D. Griffin MD
Title
Chair, Department of Medical Oncology
Experience/Biography
James D. Griffin received his medical degree from Harvard
Medical School in 1974. After residency training in internal
medicine at Johns Hopkins Hospital, he completed a hematology
fellowship at Massachusetts General Hospital and a medical
oncology fellowship at Dana-Farber. In 1981, he joined the staff of
Dana-Farber, where he currently is director of the Leukemia
Program and chair of the Department of Medical Oncology.
From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a
professor of Medicine at Harvard Medical School and currently sits
on the scientific advisory boards of the Lombardi Cancer Center at
Georgetown University and the Johns Hopkins Cancer Center and
Case Western Cancer Center.
Jay R. Harris MD
Title
Chair, Department of Radiation Oncology
Experience/Biography
Jay R. Harris, MD received his medical degree from Stanford
University in 1970. He trained in radiation oncology at the Harvard
Joint Center for Radiation Therapy, and joined the Dana-Farber
staff in 1977. Dr. Harris chairs the Department of Radiation
Oncology at Dana-Farber, Brigham and Women's Hospital, and
Boston Children's Hospital, which constitute the Longwood
Radiation Oncology Center. He is also a professor of Radiation
Oncology at Harvard Medical School.
Deborah Hicks
Title
Senior Vice President for Human Resources
Experience/Biography
Deborah Hicks joined Dana-Farber as the Senior Vice President
for Human Resources in 2011. Prior to joining Dana-Farber, Hicks
served as the associate dean and chief human resources officer
at Harvard Medical School.
She joined Harvard Medical School in January 2009. Previously,
Hicks was the vice president of Human Resources at Harvard
Pilgrim Health Care (HPHC), joining HPHC in 1988 and becoming
vice president of Human Resources and part of the leadership
team in 1999, where she was instrumental in supporting the
organization during the turnaround of HPHC from receivership to
profitability.
She currently serves as chair of the Board of the New England
Human Resources Association, holds a master's degree in
Counseling Psychology/Organizational Management from Antioch
University, and a bachelor's degree from the University of
Massachusetts at Amherst.
15
Joseph Jacobson MD
Title
Chief Quality Officer
Experience/Biography
Joseph Jacobson, MD, joined Dana-Farber Cancer Institute in
2011 as the Institute's first Chief Quality Officer, overseeing
clinical quality programs across Dana-Farber and its affiliates, and
representing Dana-Farber in regional and national quality
improvement efforts. He focuses on clinical process measurement
and improvement, efficiency and effectiveness of care, and quality
leadership development. He is also a member of and practicing
physician in our Thoracic Oncology Program.
Before joining Dana-Farber, Dr. Jacobson served as the Chairman
of Medicine at North Shore Medical Center. As part of the
Partners HealthCare system, he co-developed and currently codirects the Partners Clinical Process Improvement Leadership
Program. He has an extensive track record in quality
measurement and quality improvement, serving as a founding
member of the American Society of Clinical Oncology (ASCO)
Quality Oncology Practice Initiative, as co-developer of the
ASCO/ONS Chemotherapy Safety Standards and as recent past
Chair of the ASCO Quality of Care Committee.
Philip Kantoff MD
Title
Chief Clinical Research Officer
Experience/Biography
Philip Kantoff, MD graduated from Brown University Medical
School in 1979. After completing his internship, residency and
chief residency in internal medicine at New York University
Hospital and Bellevue Hospital, he spent four years at the National
Institutes of Health conducting research in gene therapy. He
joined Dana-Farber in 1987 and became director of what is now
the Lank Center for Genitourinary Oncology in 1988.
Dr. Kantoff is chief of the Division of Solid Tumor Oncology, leader
of the Dana-Farber/Harvard Cancer Center Prostate Cancer
Program, and director of the Prostate Cancer Specialized
Program of Research Excellence (SPORE). He is also a professor
of Medicine at Harvard Medical School. He became chief clinical
research officer in October 2006.
16
Lee M. Nadler MD
Title
Senior Vice President, Experimental Medicine
Experience/Biography
Lee M. Nadler, MD received his medical degree from Harvard
Medical School in 1973. After residency training at ColumbiaPresbyterian Medical Center, and training at the National Cancer
Institute in tumor immunology, he completed a medical oncology
fellowship at Dana-Farber, where he joined the staff in 1980.
During his tenure at Dana-Farber, he has served as chief of the
Division of Hematologic Malignancies and was the first chair of the
Department of Adult Oncology. Dr. Nadler is the Virginia and D.K.
Ludwig Professor of Medicine at Harvard Medical School and the
Pan Mass Challenge Senior Investigator at Dana-Farber.
Stuart H. Orkin MD
Title
Chairman, Department of Pediatric Oncology
Experience/Biography
Stuart H. Orkin, MD received his medical degree in 1972 from
Harvard Medical School, followed by postdoctoral research at the
National Institutes of Health and clinical training in pediatrics and
hematology-oncology at Children's Hospital Boston and DanaFarber, where he joined the faculty in 1978. Dr. Orkin is a Howard
Hughes Medical Institute Investigator and the David G. Nathan
Professor of Pediatrics at Harvard Medical School. Over the past
decade, his laboratory has defined critical nuclear regulators of
hematopoiesis.
Susan S. Paresky
Title
Senior Vice President for Development
Experience/Biography
Susan S. Paresky joined the Institute in 1997. She was associate
dean for Development at the Harvard School of Public Health,
where she executed the school's fundraising program as part of
Harvard University's $2 billion campaign. She has also held senior
positions at Brandeis University and Wheaton College. Ms.
Paresky received her business degree from Simmons Graduate
School of Management and her bachelor's degree from Wheaton
College, where she now serves as a trustee.
17
Patricia Reid Ponte RN, DNSc, FAAN
Title
Senior Vice President for Patient Care Services and Chief Nursing
Officer
Experience/Biography
Patricia Reid Ponte, RN, DNSc, FAAN, also serves as the nursing
director of the Hematology/Oncology, Bone Marrow Transplant
Program at Brigham and Women's Hospital and as the cancer
center nurse leader for Dana-Farber/Partners CancerCare. She
received her bachelor's degree in nursing from the University of
Massachusetts, Amherst, and her master's and doctorate degrees
from Boston University. Dr Reid Ponte completed a three year
Robert Wood Johnson Nurse Executive Fellowship in 2004 and
was inducted into the American Academy of Nursing.
Barrett J. Rollins MD, PhD
Title
Chief Scientific Officer
Experience/Biography
Barrett J. Rollins, MD, PhD received his doctoral degree in 1979
and medical degree in 1980 from Case Western Reserve
University and completed his internship and residency in internal
medicine at Beth Israel Hospital, Boston. He then performed
clinical and research fellowships in medical oncology at DanaFarber and joined the Institute's faculty in 1986. Dr. Rollins is
currently Professor of Medicine at Harvard Medical School.
Stephen E. Sallan MD
Title
Chief of Staff Emeritus
Experience/Biography
Stephen E. Sallan, MD joined the institute in 1973 as a trainee
before becoming a member of the staff in the Department of
Pediatric Oncology. He was named chief of staff and chairman of
the Medial Staff Executive Committee in 1995. Dr. Sallan received
his undergraduate and medical degrees from Wayne State
University. He is presently a professor of Pediatrics at Harvard
Medical School, and was named the Quick Family Senior
Investigator in 2002. In 2012, Dr. Sallan was named Chief of Staff
Emeritus.
18
Lawrence N. Shulman MD
Title
Chief of Staff, Senior Vice President for Medical Affairs, Director of
Regional Strategy Development and Director of the Center for
Global Cancer Medicine
Experience/Biography
Lawrence N. Shulman, MD became chief of staff in 2012, at which
time he also accepted leadership roles as the Institute’s director of
regional strategy development and director of the Center for
Global Cancer medicine. Prior to these positions, Dr. Schulman
had served as chief medical officer and senior vice president for
Medical Affairs at the Institute since 2002. Prior to that, he served
as Dana-Farber's vice chair for Clinical Services for the
Department of Adult Oncology. Dr. Shulman is involved in clinical
research and care for patients with breast cancer and lymphoma.
He is an associate professor of Medicine at Harvard Medical
School, and received his bachelor's degree from Syracuse
University and his medical degree from Harvard Medical School.
Steven R. Singer
Title
Senior Vice President for Communications
Experience/Biography
Steven R. Singer joined the Institute in 1997. He previously served
as director of Communications and Public Affairs and adjunct
lecturer at Harvard University's John F. Kennedy School of
Government. He has worked as a press secretary in the U.S.
House of Representatives, and is past chair of the National
Cancer Institute's Public Affairs Network. Mr. Singer received his
bachelor's degree from Colby College and a master's degree in
public administration from Harvard University's Kennedy School.
Scott J. Swanson MD
Title
Chief Surgical Officer
Experience/Biography
Scott J. Swanson, MD joined Dana-Farber as Chief Surgical
Officer in 2008. He is the Disease Center Leader of the Thoracic
Oncology Program, and leads a multidisciplinary group focused on
optimizing the experience and outcome for patients with thoracic
malignancy. Dr. Swanson is also director of the Minimally Invasive
Thoracic Surgery Program at Brigham and Women’s Hospital, and
Professor of Surgery at Harvard Medical School. He received a
bachelor’s degree, magna cum laude, from Amherst College, and
a medical degree from Harvard Medical School.
19
Annick Van den Abbeele MD
Title
Chief, Department of Imaging
Experience/Biography
Annick Van den Abbeele, MD received her BA and MD from the
Université Catholique de Louvain in Belgium. Following a
residency in Pediatrics at the Université Catholique de Louvain
and a Neonatology fellowship at Vanderbilt University Medical
Center in Nashville, TN, she completed a residency in Nuclear
Medicine and a fellowship in Radiology at Brigham and Women's
Hospital, Boston, MA and Harvard Medical School, followed by
seven years in basic sciences research. In 1994, Dr. Van den
Abbeele assumed the position of Director of Nuclear Medicine at
the Dana-Farber Cancer Institute, and in 2004 became the Clinical
Director of Radiology. In 2006, she was promoted to Chief of the
Department of Imaging. She has been a faculty member at
Harvard Medical School since 1987.
Craig A. Bunnell MD, MPH, MBA
Title
Chief Medical Officer
Experience/Biography
Craig A. Bunnell, MD, MPH, MBA became the Chief Medical
Officer and Medical Director for Adult Ambulatory Oncology in
2012. Dr. Bunnell received his bachelor's degree, summa cum
laude, from Colorado College after which he was a Thomas J.
Watson Fellow in Stockholm, Sweden. He earned his medical
degree from Harvard Medical School and his MPH from the
Harvard School of Public Health. He also earned his MBA from
the Sloan School of Management at the Massachusetts Institute of
Technology. Dr. Bunnell completed his internship, residency and
fellowship in hematology and oncology at Brigham and Women's
Hospital, where he also served as Chief Medical Resident. Dr.
Bunnell is a medical oncologist involved in research and the care
of patients with breast cancer in the Susan F. Smith Center for
Women's Cancers at Dana-Farber Cancer Institute.
Anne Gross RN, PhD
Title
Vice President Adult Ambulatory Nursing and Clinical Services
Experience/Biography
Anne Gross, RN, PhD, serves as Vice President Adult Ambulatory
Nursing and Clinical Services at Longwood and Faulkner. In this
capacity Anne is accountable for all nursing practice and nonphysician clinical services at Longwood and Faulkner. Anne has a
bachelor's from Maryville College and St. Louis University,
master's of science from Boston College, and in 2010, Dr. Gross
received her PhD in nursing from The University of Massachusetts
Boston.
20
David Read MBA, MPH
Title
Vice President for Ambulatory Care Operations, Ambulatory
Oncology, Longwood, and Ambulatory Care at the Yawkey Center
Experience/Biography
In 2012, David Read, MBA, MPH, assumed the role of Vice
President for Ambulatory Care Operations, Adult Ambulatory
Oncology, Longwood, and oversees all administrative functions
that support ambulatory care delivery at the Yawkey Center. David
supports, design and lead implementation of initiatives that create
a high-performing and efficient ambulatory care environment to
support clinicians in their daily care delivery. He will also lead
implementation of Dana-Farber’s patient access program for the
Longwood practice. David continues to serve the Department of
Medical Oncology as Department Administrator, overseeing
administration of its clinical and research functions.
Maria Papola
Title
Senior Vice President for Institute Operations
Experience/Biography
Maria Papola joined Dana-Farber Cancer Institute as the Vice
President for Facilities Management and Real Estate in 2008 and
was named Senior Vice President for Institute Operations in 2012.
Before joining Dana-Farber, Ms. Papola served as Vice President
for Corporate Real Estate Services at Saint Vincent Catholic
Medical Centers of New York. Prior to Saint Vincent's, Ms. Papola
held various management roles at Memorial Sloan-Kettering
Cancer Center after completing her administrative residency
there.
Ms. Papola holds a masters in health administration from Cornell
University and a bachelors degree in physical anthropology from
Rutgers University. She is a longtime member of several alumni
boards at Cornell where she serves as adjunct lecturer on facilities
planning.
Elizabeth Liebow MS
Title
Vice President for Clinical Planning and Network Operations
Experience/Biography
In 2012, Elizabeth Liebow, MS assumed responsibilities as
the Vice President for Clinical Planning and Network Operations.
Elizabeth's department supports key interdisciplinary clinical
planning projects and oversee the development of the Institute's
growing network of satellite clinics and management contracts.
Prior to joining Dana-Farber in 2004, Elizabeth Liebow served as
director of business development at Partners HealthCare from
1997 to 2004 and administrative director of pediatrics at Boston
Medical Center from 1994 to 1997. She has a bachelor's in
economics from Brandeis University and a masters of science in
health policy and management from Harvard School of Public
Health.
21
Staff Information
Full Time Staff
3329
Part Time Staff
794
Volunteers
64
Contractors
0
Retention Rate
81%
Staff Demographics - Ethnicity
African American/Black
365
Asian American/Pacific Islander
749
Caucasian
2671
Hispanic/Latino
224
Native American/American Indian
1
Other
113 multi-race and unspecified
Staff Demographics - Gender
Male
794
Female
3329
Unspecified
0
Formal Evaluations
CEO Formal Evaluation
Yes
CEO/Executive Formal Evaluation Frequency
Annually
Senior Management Formal Evaluation
Yes
Senior Management Formal Evaluation Frequency
Annually
NonManagement Formal Evaluation
Yes
Non Management Formal Evaluation Frequency
Semi-Annually
Plans & Policies
Organization has a Fundraising Plan?
Under Development
Organization has a Strategic Plan?
No
Organization Policy and Procedures
Under Development
Nondiscrimination Policy
Under Development
Whistleblower Policy
No
Document Destruction Policy
No
22
Board & Governance
Board Chair
Board Chair
Mr. Joshua Bekenstein
Company Affiliation
Bain Capital Partners, LLC
Term
Jan 2011 to 0
Email
[email protected]
Board Members
Name
Affiliation
Status
Andrea R. Abraham
n/a
Gerhard R. Andlinger
Andlinger & Co.
Michael Andrews
n/a
David Auerbach
n/a
Delores Barr Weaver
n/a
David Barrett
Polaris Venture Partners
Robert A. Belfer
Belfer Management LLC
Dr. Edward J. Benz Jr.
Dana-Farber Cancer Institute
Roger Berkowitz
Legal Sea Foods
Armin G. Biller
n/a
Jack Blais
BlaisCo, LLC
Betty Ann Blum
n/a
Justice Stephen G. Breyer
Supreme Court of The United
States
Honorary Frederick L. Brown
Massachusetts Appeals Court
Dr. Craig Bunnell
Dana-Farber Cancer Institute
J. Gary Burkhead
n/a
Kennett F. Burnes Esq.
n/a
Stephen J. Burton
CBS4
Richard A. Cantor
Cantor Foundation
Michael A. Champa
n/a
George A. Cloutier
American Management Services
Marc A. Cohen
OPNET Technologies
Joseph F. Cotter
n/a
Gary L. Countryman
Liberty Mutual Insurance
Companies
Howard Cox
Greylock
Neal J. Curtin Esq.
Bingham McCutchen, LLP
Alice Cutler
n/a
Charles A. Dana III
Newport Shipyard Corporation
Lee S. Daniels
n/a
Nader F. Darehshori
n/a
Peter de Roetth
Account Management, LLC
23
David A. Dechman
Summit Rock Advisors
Emily F. DiMaggio
n/a
Jim Donovan
Goldman Sachs Corp.
James M. Dow
n/a
John P. Dunfey
New Hampshire Charitable
Foundation
Donald Dwares
n/a
Michael Eisenson
Charlesbank Capital Partners, LLC
Ed Eskandarian
Arnold Worldwide Partners
John S. Farber
Old Trail School
Stephen B. Farber
Concordia Group
Thomas A. Farrington
Prostate Health Education
Network, Inc.
James L. Fine
Levy & Droney P.C.
Stephen Fine
The Biltrite Corporation
Robert First
n/a
Deborah First
Deborah First Communications
Charles Forman
n/a
Dr. Emil Frei III
n/a
Michael Frieze
Gordon Brothers Group
Dozier Gardner
Fernwood Advisors
Dr. Arthur Gelb
Four Sigma Corporation
Nancy Gibson
n/a
William M. Gillen
Eaton Vance Investment Counsel
Michael Gordon
Vinik Asset Management
Abraham D. Gosman
n/a
Dr. James D. Griffin
Dana-Farber Cancer Institute
Richard L. Grubman
Highfields Capital Management
Judy Hale
Granite Telecommunications LLC
David Harkins
Thomas H. Lee Partners, LP
Marian L. Heard
n/a
Frances Heller
n/a
Alan Hirschfield
Norman Hirschfield & Co.
Thomas F. Holt Jr., Esq.
K&L Gates
Barbara H. Hugus PhD
n/a
Jane P. Jamieson
n/a
Glenn M. Johnson
Northland Investment Corporation
Scott L. Kafker
Massachusetts Appeals Court
William Karol
Koda Enterprises Group, LLC
Stephen B. Kay
Goldman, Sachs, & Company
Patricia D. Kelsey
n/a
Michelle Kessler
n/a
Michael J. Kittredge
n/a
Brian J. Knez
Castanea Partners
24
Ruth Kopelman
n/a
Steven P. Koppel
n/a
Paul B. Kopperl
n/a
Stephen P. Koster Esq.
Vacovec, Mayotte & Singer, LLP
Daniel Kraft
International Forest Products
Robert K. Kraft
The Kraft Group
Sandra G. Krakoff
n/a
Phyllis Krock
n/a
Althea Lank
n/a
Rebecca Latimore
IBM Institute For Business Value
Jonathan S. Lavine
Bain Capital Partners, LLC
Kenneth H.M. Leet
Granite Ridge LLP
John Legere
n/a
Kenneth R. Levine
Seaview Consulting, Inc.
Roger A. Lockwood
Lockwood/McKinnon Group
Richard K. Lubin
Berkshire Partners, LLC
Bradley Lucas
Anton Lucas, Inc.
Larry Lucchino
Boston Red Sox
Hildegarde E. Mahoney
Harvard Mahoney Neuroscience
Inst.
Peter Maich
n/a
Roger M. Marino
Marino Capital Corp
John L. Marshall III
Marshall Properties, Inc.
Thomas J. May
NSTAR
William F. McCall Jr.
McCall & Almy Inc.
Joseph C. McNay
Essex Investment Mgmt. Co., Inc.
William F. Meagher Jr.
n/a
David S. Moross
Falconhead Capital
Richard P. Morse
n/a
Dr. David G. Nathan
Dana-Farber Cancer Institute
George A. Neale
Liberty Mutual Insurance
Companies
Charlie Nirenberg
First Merchants Group
Joseph E. Norberg
n/a
John J. O'Connor
n/a
Brian O'Connor
Miles Logue Financial Group
Vincent M. O'Reilly
Boston College
Dr. Stuart H. Orkin
Dana-Farber Cancer Institute
Edward O. Owens
Owens Companies, Inc.
Peter Palandjian
Intercontinental Real Estate Corp.
Dr. Arthur M. Pappas
UMass Medical School
Ted Pasquarello
Paris Trust LLC
Jean F. Pearlstein
n/a
David B. Perini
n/a
25
Eileen Perini
n/a
Jennifer Perini
Everyman Pictures
Steven P. Perlmutter Esq.
Robinson & Cole
Susan M. Poduska
Poduska Family Foundation
Betsy Pohl
MFS Investment Management
Alison Poorvu Jaffe
n/a
William J. Poutsiaka
Chartis Insurance
Dr. Kathleen M. Randolph
n/a
John M. Randolph
n/a
Jim Rappaport
New Boston Fund, Inc.
John P. Reardon Jr.
Harvard
Sumner M. Redstone
National Amusements, Inc.
Shari E. Redstone
National Amusements, Inc.
Amy Reiner
n/a
Robert L. Reynolds
Putnam Investments
Dr. Barrett J. Rollins
Dana-Farber Cancer Institute
Ann M. Rosenberg
D'Vine Wine
Harvey Rosenthal
n/a
Edward F. Rover
Charles A. Dana Foundation
Robert J. Sachs Esq.
Continental Consulting Group, LLC
James Sadowksy
Williams Distributing Corporation
Barbara Sadowsky
n/a
Dr. Stephen E. Sallan
Dana-Farber Cancer Institute
Marjorie Salmon
Assoc. Counselors and
Psychotherapists
Malcolm S. Salter
Harvard Business School
H. Terrence Samway
n/a
Rebecca L. Sanders
Destin Realty, Inc.
Judith P. Schlager
The Bullfinch Companies, Inc.
Richard N. Seaman
Seaman Corporation
Thomas P. Sellers
n/a
Laura Jeanne Sen
BJ's Wholesale Club Incorporated
Paul Severino
n/a
Jean S. Sharf
Sharf Marketing Group, Inc.
Paula L. Sidman
The Beacon Companies
Susan F. Smith
n/a
Richard A. Smith
Smith Management Company
Amy Smith Berylson
Chestnut Hill Ventures
Ruth F. Snider
n/a
Jerry Socol
The Socol Group
Gloria H. Spivak
n/a
Robert Stansky
Fidelity Investments
William Starr
Pan Mass Challenge
James Stoneman
Seljim Investments
26
Patrick J. Sullivan
Game Creek Video LLC
Fifi Swerling Kellem
Dana-Farber Cancer Institute
Jean C. Tempel
First Light Capital
Beth F. Terrana
n/a
David Ting
Mugar Enterprises, Inc.
J. Wayne Weaver
n/a
Karen L. Webster
Market Platform Dynamics
Laura Weissman Davis
n/a
T. Conrad Wetterau
Quality Beverage Co.
Gregory A. White
Thomas H. Lee Partners, LP
Frederica M. Williams
Whittier Street Health Center
Winnie Wong
n/a
Carl Yastrzemski
Eaton Vance Investment Counsel
Jay Yost
Fidelity Investments
Mortimer B. Zuckerman
Boston Properties
Board Demographics - Ethnicity
African American/Black
11
Asian American/Pacific Islander
2
Caucasian
141
Hispanic/Latino
0
Native American/American Indian
0
Other
0 1 Middle Eastern
Board Demographics - Gender
Male
113
Female
42
Unspecified
0
Board Information
Number of Full Board Meetings Annually
4
Board Meeting Attendance %
75%
Written Board Selection Criteria?
No
Written Conflict of Interest Policy?
Under Development
Percentage Making Monetary Contributions
100%
Constituency Includes Client Representation
Yes
Standing Committees
27
Audit
Communications / Promotion / Publicity / Public Relations
Community Outreach / Community Relations
Compensation
Development / Fund Development / Fund Raising / Grant Writing / Major Gifts
Executive
Finance
Investment
Personnel
Scientific Advisory
Campus Planning and Development
Comments
CEO Comments
Please Note: We do not disclose the percentage of board members making monetary contributions;
the value is not 0%.
28
Financials
Fiscal Year
Fiscal Year Start
Oct 01, 2011
Fiscal Year End
Sept 30, 2012
Projected Revenue
$1,000,863,483.00
Projected Expenses
$994,919,900.00
Endowment?
Yes
Endowment Value
$351316236.00
Spending Policy
Percentage
Percentage
7%
Credit Line?
Yes
Reserve Fund?
Yes
Months Reserve Fund Covers
0
Detailed Financials
Revenue and Expenses
Fiscal Year
Total Revenue
Total Expenses
Revenue Sources
Fiscal Year
Foundation and Corporation
Contributions
Government Contributions
Federal
State
Local
Unspecified
Individual Contributions
Indirect Public Support
Earned Revenue
Investment Income, Net of Losses
Membership Dues
Special Events
Revenue In-Kind
Other
2013
$1,056,841,650
$1,023,723,858
2012
$1,021,271,591
$982,077,009
2011
$1,002,464,148
$965,097,718
2013
--
2012
--
2011
--
$132,889,339
---$132,889,339
$239,084,267
$466,445
$643,884,073
$224,324
-$19,079,607
-$21,213,595
$143,574,943
---$143,574,943
$235,972,261
$370,559
$607,158,776
$293,433
-$17,018,157
-$16,883,462
$164,905,675
---$164,905,675
$255,325,600
$370,150
$545,363,835
$332,089
-$18,215,647
-$17,951,152
29
Expense Allocation
Fiscal Year
Program Expense
Administration Expense
Fundraising Expense
Payments to Affiliates
Total Revenue/Total Expenses
Program Expense/Total Expenses
Fundraising Expense/Contributed
Revenue
Assets and Liabilities
Fiscal Year
Total Assets
Current Assets
Long-Term Liabilities
Current Liabilities
Total Net Assets
Short Term Solvency
Fiscal Year
Current Ratio: Current Assets/Current
Liabilities
Long Term Solvency
Fiscal Year
Long-Term Liabilities/Total Assets
Top Funding Sources
Fiscal Year
Top Funding Source & Dollar Amount
Second Highest Funding Source & Dollar
Amount
Third Highest Funding Source & Dollar
Amount
2013
$836,192,565
$166,191,419
$21,339,874
-1.03
82%
5%
2012
$831,685,201
$130,473,286
$19,918,522
-1.04
85%
5%
2011
$821,087,868
$127,308,133
$16,701,717
-1.04
85%
4%
2013
$1,790,428,000
$311,537,000
$414,739,000
$193,306,000
$1,182,383,000
2012
$1,605,048,000
$248,483,000
$394,630,000
$174,255,000
$1,036,163,000
2011
$1,487,622,000
$201,452,000
$379,805,000
$166,734,000
$941,083,000
2013
1.61
2012
1.43
2011
1.21
2013
23%
2012
25%
2011
26%
2013
---
2012
---
2011
---
--
--
--
Capital Campaign
Currently in a Capital Campaign?
No
Capital Campaign Anticipated in Next 5 Years?
Yes
Comments
Foundation Staff Comments
Financial summary data in the charts and graphs above for the revenue and expenses are per the
organization's IRS Form 990s; asset and liability data is per the audited financials. Contributions
from foundations and corporations are listed under individuals when the breakout was not available.
Created 05.08.2017.
Copyright © 2017 The Boston Foundation
30